FDA Warns of Risks With Off-Label Fat Dissolver Use

The U.S. Food and Drug Administration (FDA) has issued a warning regarding the potential for serious adverse events associated with the unapproved use of deoxycholic acid injections, commonly known by the brand name Kybella, outside of its intended submental (under the chin) fat treatment area. This update to the product's labeling aims to inform healthcare providers and patients about the risks of neuromuscular damage and other significant complications that can arise from off-label administration.

Deoxycholic acid is a naturally occurring substance that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath the chin, it destroys fat cells, leading to a noticeable reduction in fullness. However, the FDA's review of adverse event reports has indicated that when this injectable is used in other areas of the body, such as the jawline, neck, or other body contours, it can lead to unintended and potentially severe consequences. These risks include damage to nerves that control muscle movement, resulting in muscle weakness or paralysis in the treated area and surrounding regions. Such neuromuscular effects can manifest as difficulty swallowing, speaking, or even breathing in extreme cases, depending on the proximity of the injection site to critical nerves and muscles.

The FDA's updated labeling specifically highlights the increased risk of these adverse events when deoxycholic acid is administered in areas other than the submental fat pad. The agency emphasizes that the safety and efficacy of deoxycholic acid injections have not been established for any indication other than the treatment of moderate to severe convexity or fullness associated with submental fat in adults. Healthcare professionals are urged to adhere strictly to the approved indications and administration guidelines for deoxycholic acid products to mitigate these risks. Patients considering treatment with deoxycholic acid injections should discuss the approved uses, potential benefits, and known risks thoroughly with their healthcare provider, ensuring that the treatment plan aligns with the FDA-approved indications.

This regulatory action underscores the importance of using prescription medications only as directed by a healthcare professional and for the conditions for which they have been approved. The FDA continues to monitor the safety of medical products and will provide further updates or guidance as necessary. The warning serves as a critical reminder for both medical practitioners and consumers about the potential dangers of using treatments off-label, especially when injectable substances are involved, and the necessity of relying on evidence-based medical practices.